120 related articles for article (PubMed ID: 38553362)
1. Volumetric Response and Survival of Patients With Bulky IDH-Mutated Grade 3 Glioma Managed With FET-FDG-Guided Integrated Boost IMRT.
Mills D; Horsley P; Venkatasha V; Back M
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):343-352. PubMed ID: 38553362
[TBL] [Abstract][Full Text] [Related]
2. Reducing radiation dose to normal brain through a risk adapted dose reduction protocol for patients with favourable subtype anaplastic glioma.
Back M; LeMottee M; Crasta C; Bailey D; Wheeler H; Guo L; Eade T
Radiat Oncol; 2017 Mar; 12(1):46. PubMed ID: 28253929
[TBL] [Abstract][Full Text] [Related]
3. Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy.
Metz G; Jayamanne D; Wheeler H; Wong M; Cook R; Little N; Parkinson J; Kastelan M; Brown C; Back M
BMC Neurol; 2022 Jan; 22(1):24. PubMed ID: 35027006
[TBL] [Abstract][Full Text] [Related]
4. Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma.
Back M; Jayamanne D; Brazier D; Bailey D; Hsiao E; Guo L; Wheeler H
J Clin Neurosci; 2019 Jan; 59():68-74. PubMed ID: 30446361
[TBL] [Abstract][Full Text] [Related]
5. Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma.
Back MF; Jayamanne D; Back E; Kastelan M; Khasraw M; Wong M; Brown C; Wheeler H
Cancer; 2019 Oct; 125(19):3457-3466. PubMed ID: 31251406
[TBL] [Abstract][Full Text] [Related]
6. Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
Back M; Jayamanne D; Brazier D; Newey A; Bailey D; Schembri G; Hsiao E; Khasraw M; Wong M; Kastelan M; Brown C; Wheeler H
Strahlenther Onkol; 2020 Jan; 196(1):31-39. PubMed ID: 31028406
[TBL] [Abstract][Full Text] [Related]
7. Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Back M; Jayamanne DT; Brazier D; Newey A; Bailey D; Schembri GP; Hsiao E; Khasraw M; Wong M; Kastelan M; Guo L; Clarke S; Wheeler H
J Med Imaging Radiat Oncol; 2019 Apr; 63(2):272-280. PubMed ID: 30677248
[TBL] [Abstract][Full Text] [Related]
8. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
Sutera P; Kalash R; Flickinger J; Engh J; Heron DE
Am J Clin Oncol; 2019 Jan; 42(1):27-35. PubMed ID: 29912004
[TBL] [Abstract][Full Text] [Related]
10. Association of MRI Volume Parameters in Predicting Patient Outcome at Time of Initial Diagnosis of Glioblastoma.
Lau KS; Ruisi I; Back M
Brain Sci; 2023 Nov; 13(11):. PubMed ID: 38002539
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
[TBL] [Abstract][Full Text] [Related]
13. The prognosis of gliomas with different molecular subtypes in the era of intensity-modulated radiation therapy (IMRT).
Zhong Q; Luo D; Chen D; Li X; Du Q; Liang Q; Li J; Zhu X
Aging (Albany NY); 2023 Aug; 15(15):7781-7793. PubMed ID: 37556350
[TBL] [Abstract][Full Text] [Related]
14. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
15. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
[TBL] [Abstract][Full Text] [Related]
17. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
[TBL] [Abstract][Full Text] [Related]
18. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
[TBL] [Abstract][Full Text] [Related]
19. Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.
Huang RY; Young RJ; Ellingson BM; Veeraraghavan H; Wang W; Tixier F; Um H; Nawaz R; Luks T; Kim J; Gerstner ER; Schiff D; Peters KB; Mellinghoff IK; Chang SM; Cloughesy TF; Wen PY
Neuro Oncol; 2020 Dec; 22(12):1822-1830. PubMed ID: 32328652
[TBL] [Abstract][Full Text] [Related]
20. Multifocal high-grade glioma radiotherapy safety and efficacy.
Fleischmann DF; Schön R; Corradini S; Bodensohn R; Hadi I; Hofmaier J; Forbrig R; Thon N; Dorostkar M; Belka C; Niyazi M
Radiat Oncol; 2021 Aug; 16(1):165. PubMed ID: 34454558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
